Vontobel Holding Ltd. Lowers Position in Autolus Therapeutics plc (NASDAQ:AUTL)

Vontobel Holding Ltd. decreased its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 26.6% during the 4th quarter, Holdings Channel.com reports. The fund owned 147,419 shares of the company’s stock after selling 53,522 shares during the period. Vontobel Holding Ltd.’s holdings in Autolus Therapeutics were worth $346,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. Dumont & Blake Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics in the 4th quarter valued at about $35,000. Arkadios Wealth Advisors acquired a new position in Autolus Therapeutics during the fourth quarter worth $47,000. Capstone Investment Advisors LLC acquired a new position in shares of Autolus Therapeutics in the third quarter worth $51,000. Avanza Fonder AB acquired a new position in shares of Autolus Therapeutics in the fourth quarter worth $75,000. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Autolus Therapeutics by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock valued at $139,000 after purchasing an additional 14,959 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on AUTL shares. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price for the company in a report on Friday, November 15th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics has a consensus rating of “Buy” and a consensus target price of $10.40.

Autolus Therapeutics Trading Down 2.5 %

NASDAQ AUTL opened at $1.95 on Friday. The stock’s 50 day moving average is $2.24 and its two-hundred day moving average is $3.21. The company has a market capitalization of $518.88 million, a price-to-earnings ratio of -1.61 and a beta of 2.02. Autolus Therapeutics plc has a 1-year low of $1.87 and a 1-year high of $6.70.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.